SK17432000A3 - Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený - Google Patents

Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený Download PDF

Info

Publication number: SK17432000A3
Authority: SK; Slovakia
Prior art keywords: mmol; octane; dioxabicyclo; compound; solution
Prior art date: 1998-05-26

Application number

SK1743-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Guangyi Wang

Original Assignee

Icn Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-26

Filing date

1999-05-24

Publication date

2001-07-10

1999-05-24 Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.

2001-07-10 Publication of SK17432000A3 publication Critical patent/SK17432000A3/sk

Links

239000002777 nucleoside Substances 0.000 title abstract description 47
125000003835 nucleoside group Chemical group 0.000 title abstract description 23
125000002619 bicyclic group Chemical group 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 63
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 25
239000000203 mixture Substances 0.000 claims description 35
229910052739 hydrogen Inorganic materials 0.000 claims description 20
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 7
239000001226 triphosphate Substances 0.000 claims description 7
230000000840 anti-viral effect Effects 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
235000011178 triphosphate Nutrition 0.000 claims description 6
229940113082 thymine Drugs 0.000 claims description 5
229940035893 uracil Drugs 0.000 claims description 5
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 claims description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
229930024421 Adenine Natural products 0.000 claims description 2
101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 2
102100034195 Thrombopoietin Human genes 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
229960000643 adenine Drugs 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000000304 alkynyl group Chemical group 0.000 claims description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
229940104302 cytosine Drugs 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 5
241000700721 Hepatitis B virus Species 0.000 claims 2
241000725303 Human immunodeficiency virus Species 0.000 claims 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
239000000178 monomer Substances 0.000 claims 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
239000001177 diphosphate Substances 0.000 claims 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
235000011180 diphosphates Nutrition 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 19
238000007363 ring formation reaction Methods 0.000 abstract description 2
108091092742 A-DNA Proteins 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
229940127073 nucleoside analogue Drugs 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
239000000243 solution Substances 0.000 description 58
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
238000002360 preparation method Methods 0.000 description 38
-1 nucleoside triphosphates Chemical class 0.000 description 34
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
238000005481 NMR spectroscopy Methods 0.000 description 28
239000000741 silica gel Substances 0.000 description 28
229910002027 silica gel Inorganic materials 0.000 description 28
239000007787 solid Substances 0.000 description 26
238000004587 chromatography analysis Methods 0.000 description 25
239000011734 sodium Substances 0.000 description 23
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
238000000034 method Methods 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
235000019439 ethyl acetate Nutrition 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
239000012267 brine Substances 0.000 description 13
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 11
238000009833 condensation Methods 0.000 description 11
230000005494 condensation Effects 0.000 description 11
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 11
239000000047 product Substances 0.000 description 11
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 10
150000008300 phosphoramidites Chemical class 0.000 description 10
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
238000002844 melting Methods 0.000 description 9
230000008018 melting Effects 0.000 description 9
150000003833 nucleoside derivatives Chemical class 0.000 description 9
239000012044 organic layer Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
239000006260 foam Substances 0.000 description 8
239000006188 syrup Substances 0.000 description 8
235000020357 syrup Nutrition 0.000 description 8
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
238000010992 reflux Methods 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
229910021529 ammonia Inorganic materials 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
150000001720 carbohydrates Chemical class 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
238000007327 hydrogenolysis reaction Methods 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 6
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 6
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229940125797 compound 12 Drugs 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
IQFYYKKMVGJFEH-RNJXMRFFSA-N 1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-RNJXMRFFSA-N 0.000 description 4
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
108020004394 Complementary RNA Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
101710163270 Nuclease Proteins 0.000 description 4
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
239000003184 complementary RNA Substances 0.000 description 4
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 3
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
239000010410 layer Substances 0.000 description 3
MXSMRDDXWJSGMC-UHFFFAOYSA-N n-(6-oxo-3,7-dihydropurin-2-yl)acetamide Chemical compound N1C(NC(=O)C)=NC(=O)C2=C1N=CN2 MXSMRDDXWJSGMC-UHFFFAOYSA-N 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
NYHBQMYGNKIUIF-BDXYJKHTSA-N 2-amino-9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one Chemical class NC1=NC(O)=C2N=CN([C@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1 NYHBQMYGNKIUIF-BDXYJKHTSA-N 0.000 description 2
FINYOTLDIHYWPR-UHFFFAOYSA-N 2-cyanoethoxy-n,n-di(propan-2-yl)phosphonamidous acid Chemical compound CC(C)N(C(C)C)P(O)OCCC#N FINYOTLDIHYWPR-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
108010042833 7,8-diaminopelargonic acid aminotransferase Proteins 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
BSAQJLSFFJIXER-UHFFFAOYSA-N CCCCCCCCOP(CCC#N)(N(C(C)C)C(C)C)(O)O Chemical compound CCCCCCCCOP(CCC#N)(N(C(C)C)C(C)C)(O)O BSAQJLSFFJIXER-UHFFFAOYSA-N 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000005457 optimization Methods 0.000 description 2
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
GFJTUNWHUFZECA-JEAXJGTLSA-N (4S,5R)-5-(hydroxymethyl)-2-methyl-3-methylideneoxolane-2,4-diol Chemical compound CC1(O)O[C@H](CO)[C@@H](O)C1=C GFJTUNWHUFZECA-JEAXJGTLSA-N 0.000 description 1
GMTBQDMFSNYCFC-ZOVQDZKKSA-N (4S,5R)-5-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-methyl-3-methylidene-4-phenylmethoxyoxolan-2-ol Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1OC(C)(O)C(=C)[C@@H]1OCC1=CC=CC=C1 GMTBQDMFSNYCFC-ZOVQDZKKSA-N 0.000 description 1
WHJNVCIXZWGLTQ-UHFFFAOYSA-N (6-chloropurin-9-yl)-trimethylsilane Chemical compound N1=CN=C2N([Si](C)(C)C)C=NC2=C1Cl WHJNVCIXZWGLTQ-UHFFFAOYSA-N 0.000 description 1
JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 1
KIYOIENTFJGNAB-UHFFFAOYSA-N 1-acetyl-2-amino-7h-purin-6-one Chemical compound O=C1N(C(=O)C)C(N)=NC2=C1NC=N2 KIYOIENTFJGNAB-UHFFFAOYSA-N 0.000 description 1
CCZMQYGSXWZFKI-UHFFFAOYSA-N 1-chloro-4-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=C(OP(Cl)(Cl)=O)C=C1 CCZMQYGSXWZFKI-UHFFFAOYSA-N 0.000 description 1
CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
ZOYUGIKLXBEGIN-UHFFFAOYSA-N 3,4-dioxabicyclo[3.2.1]octane Chemical group C1C2CCC1OOC2 ZOYUGIKLXBEGIN-UHFFFAOYSA-N 0.000 description 1
QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
UCTGPBWORFETEK-UHFFFAOYSA-N 4,7-dioxabicyclo[3.2.1]octane Chemical compound C1C2COC1CCO2 UCTGPBWORFETEK-UHFFFAOYSA-N 0.000 description 1
BCZUPRDAAVVBSO-MJXNYTJMSA-N 4-acetylcytidine Chemical compound C1=CC(C(=O)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BCZUPRDAAVVBSO-MJXNYTJMSA-N 0.000 description 1
JXDZQJSQAMAXEL-UHFFFAOYSA-N 5-methyl-1,3-bis(trimethylsilyl)pyrimidine-2,4-dione Chemical compound CC1=CN([Si](C)(C)C)C(=O)N([Si](C)(C)C)C1=O JXDZQJSQAMAXEL-UHFFFAOYSA-N 0.000 description 1
KLEVZXOPXBEUHN-FPVIDPCTSA-N 6-amino-6-benzoyl-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=CC(N)(C(=O)C=2C=CC=CC=2)NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KLEVZXOPXBEUHN-FPVIDPCTSA-N 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
UKBQRFPBUSSYDL-UHFFFAOYSA-N N1(C(=O)NC(=O)C(C)=C1)C12OCCC(OC1)C2 Chemical compound N1(C(=O)NC(=O)C(C)=C1)C12OCCC(OC1)C2 UKBQRFPBUSSYDL-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
KFVREYFOFOLMIE-UHFFFAOYSA-N O.O.O.O.[Na+].[Na+].[Na+].[O-]B([O-])[O-] Chemical compound O.O.O.O.[Na+].[Na+].[Na+].[O-]B([O-])[O-] KFVREYFOFOLMIE-UHFFFAOYSA-N 0.000 description 1
PYPRPMDWAJYOCK-UHFFFAOYSA-N OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O Chemical compound OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O PYPRPMDWAJYOCK-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
WVIRMBKINXCFDQ-UHFFFAOYSA-N [2,4-bis(trimethylsilyl)pyrimidin-5-yl]-trimethylsilane Chemical class C[Si](C)(C)C1=NC=C([Si](C)(C)C)C([Si](C)(C)C)=N1 WVIRMBKINXCFDQ-UHFFFAOYSA-N 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
125000000848 adenin-9-yl group Chemical group [H]N([H])C1=C2N=C([H])N(*)C2=NC([H])=N1 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
238000006197 hydroboration reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000003328 mesylation reaction Methods 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000003294 thymin-1-yl group Chemical group [H]N1C(=O)N(*)C([H])=C(C1=O)C([H])([H])[H] 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)

SK1743-2000A 1998-05-26 1999-05-24 Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený SK17432000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8671998P	1998-05-26	1998-05-26
PCT/US1999/011442 WO1999060855A1 (en)	1998-05-26	1999-05-24	Novel nucleosides having bicyclic sugar moiety

Publications (1)

Publication Number	Publication Date
SK17432000A3 true SK17432000A3 (sk)	2001-07-10

Family

ID=22200439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1743-2000A SK17432000A3 (sk)	1998-05-26	1999-05-24	Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený

Country Status (21)

Country	Link
US (1)	US6403566B1 (zh)
EP (1)	EP1082012A4 (zh)
JP (1)	JP2002516256A (zh)
CN (1)	CN1311630A (zh)
AU (1)	AU757724B2 (zh)
BR (1)	BR9911596A (zh)
CA (1)	CA2333380A1 (zh)
HR (1)	HRP20000751A2 (zh)
HU (1)	HUP0102152A3 (zh)
IL (1)	IL139420A0 (zh)
MX (1)	MXPA00011473A (zh)
NO (1)	NO20005938L (zh)
NZ (1)	NZ507913A (zh)
PL (1)	PL344303A1 (zh)
RU (1)	RU2211223C2 (zh)
SI (1)	SI20474A (zh)
SK (1)	SK17432000A3 (zh)
UA (1)	UA61997C2 (zh)
WO (1)	WO1999060855A1 (zh)
YU (1)	YU73600A (zh)
ZA (1)	ZA200006315B (zh)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040033977A1 (en) *	1990-08-14	2004-02-19	Bennett C. Frank	Oligonucleotide modulation of cell adhesion
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
CA2279675A1 (en) *	1995-12-15	1997-06-16	Enzo Therapeutics, Inc.	Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses
US6833361B2 (en) *	1998-05-26	2004-12-21	Ribapharm, Inc.	Nucleosides having bicyclic sugar moiety
US7084125B2 (en)	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
US6900186B1 (en) *	1999-06-21	2005-05-31	Murdock Children's Research Institute	Method for the prophylaxis and/or treatment of medical disorders
EP2957568B1 (en) *	2002-11-05	2016-12-21	Ionis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CN1852915A (zh) *	2003-07-25	2006-10-25	艾登尼科斯（开曼）有限公司	治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
US7480382B2 (en) *	2003-09-30	2009-01-20	Microsoft Corporation	Image file container
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
EP1976567B1 (en)	2005-12-28	2020-05-13	The Scripps Research Institute	Natural antisense and non-coding rna transcripts as drug targets
HUE040417T2 (hu)	2007-05-04	2019-03-28	Marina Biotech Inc	Aminosavlipidek és alkalmazásuk
US20100015708A1 (en) *	2008-06-18	2010-01-21	Mdrna, Inc.	Ribonucleic acids with non-standard bases and uses thereof
WO2010040112A2 (en) *	2008-10-03	2010-04-08	Curna, Inc.	Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
CN104382853A (zh)	2008-10-16	2015-03-04	玛瑞纳生物技术有限公司	基因沉默治疗剂的脂质体有效递送方法和组合物
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
RU2620970C2 (ru)	2008-12-04	2017-05-30	КьюРНА,Инк.,	Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
MX358603B (es)	2008-12-04	2018-08-28	Curna Inc	Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
EP2370581B1 (en)	2008-12-04	2016-08-03	CuRNA, Inc.	Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
EP3009150B1 (en)	2009-02-12	2019-11-13	CuRNA, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010107733A2 (en)	2009-03-16	2010-09-23	Curna, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
ES2627763T3 (es)	2009-03-17	2017-07-31	Curna, Inc.	Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
EP2427552B1 (en)	2009-05-06	2016-11-16	CuRNA, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US9155754B2 (en)	2009-05-06	2015-10-13	Curna, Inc.	Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
CA2761248C (en)	2009-05-08	2023-03-14	Joseph Collard	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
WO2010135695A2 (en)	2009-05-22	2010-11-25	Curna, Inc.	TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
ES2618576T3 (es)	2009-05-28	2017-06-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
KR101801404B1 (ko)	2009-06-16	2017-12-20	큐알엔에이, 인크.	콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
KR101702689B1 (ko)	2009-06-16	2017-02-06	큐알엔에이, 인크.	Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
JP6073133B2 (ja)	2009-06-24	2017-02-01	クルナ・インコーポレーテッド	腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
ES2583691T3 (es)	2009-06-26	2016-09-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
US20120252869A1 (en)	2009-07-24	2012-10-04	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
KR101802536B1 (ko)	2009-08-05	2017-11-28	큐알엔에이, 인크.	인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
WO2011019815A2 (en)	2009-08-11	2011-02-17	Curna, Inc.	Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
CN102482670B (zh)	2009-08-21	2018-06-15	库尔纳公司	通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
CA2771172C (en)	2009-08-25	2021-11-30	Opko Curna, Llc	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2664591T3 (es)	2009-09-25	2018-04-20	Curna, Inc.	Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
WO2011052436A1 (ja) *	2009-10-29	2011-05-05	国立大学法人大阪大学	架橋型人工ヌクレオシドおよびヌクレオチド
NO2513310T3 (zh)	2009-12-16	2018-03-31
EP2515947B1 (en)	2009-12-23	2021-10-06	CuRNA, Inc.	Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
JP5934106B2 (ja)	2009-12-23	2016-06-15	カッパーアールエヌエー，インコーポレイテッド	肝細胞増殖因子（ｈｇｆ）に対する天然アンチセンス転写物の阻害によるｈｇｆ関連性疾患の治療
EP2519634B1 (en)	2009-12-29	2016-06-01	CuRNA, Inc.	TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
JP5993744B2 (ja)	2009-12-29	2016-09-14	カッパーアールエヌエー，インコーポレイテッド	核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
US20120289583A1 (en)	2009-12-31	2012-11-15	Curna, Inc.	Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
NO2521784T3 (zh)	2010-01-04	2018-05-05
CA2786056C (en)	2010-01-06	2023-03-14	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
EP2524039B1 (en)	2010-01-11	2017-11-29	CuRNA, Inc.	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011091390A2 (en)	2010-01-25	2011-07-28	Opko Curna, Llc	Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2553098B1 (en)	2010-04-02	2017-10-11	CuRNA, Inc.	Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
RU2610661C2 (ru)	2010-04-09	2017-02-14	Курна, Инк.	Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
WO2011139710A1 (en)	2010-04-26	2011-11-10	Marina Biotech, Inc.	Nucleic acid compounds with conformationally restricted monomers and uses thereof
EP2625186B1 (en)	2010-04-28	2016-07-27	Ionis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
JP6005628B2 (ja) *	2010-04-28	2016-10-12	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
KR101915115B1 (ko)	2010-05-03	2018-11-05	큐알엔에이, 인크.	시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
ES2664585T3 (es)	2010-05-26	2018-04-20	Curna, Inc.	Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA
DK2576783T3 (en)	2010-05-26	2018-03-12	Curna Inc	TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
JP6023705B2 (ja)	2010-06-23	2016-11-09	カッパーアールエヌエー，インコーポレイテッド	ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
JP5986998B2 (ja)	2010-10-06	2016-09-06	カッパーアールエヌエー，インコーポレイテッド	シアリダーゼ４（ｎｅｕ４）への天然アンチセンス転写物の阻害によるｎｅｕ４関連疾患の治療
WO2012054723A2 (en)	2010-10-22	2012-04-26	Opko Curna Llc	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012061810A1 (en)	2010-11-05	2012-05-10	Miragen Therapeutics	Base modified oligonucleotides
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
CA2817371A1 (en)	2010-12-15	2012-06-21	Miragen Therapeutics	Microrna inhibitors comprising locked nucleotides
AU2012242761A1 (en)	2011-04-12	2013-10-31	Beth Israel Deaconess Medical Center, Inc.	Micro-RNA inhibitors and their uses in disease
KR20140037868A (ko)	2011-05-09	2014-03-27	더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우	폐동맥 고혈압의 치료에서 마이크로rna를 조절하는 방법
EP2718439B1 (en)	2011-06-09	2017-08-09	CuRNA, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
KR101991980B1 (ko)	2011-09-06	2019-06-21	큐알엔에이, 인크.	소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
US9751909B2 (en) *	2011-09-07	2017-09-05	Marina Biotech, Inc.	Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
HK1202053A1 (zh) *	2012-01-23	2015-09-18	Can-Fite Biopharma Ltd.	肝脏状况的治疗
CN110438125A (zh)	2012-03-15	2019-11-12	科纳公司	通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
MX355408B (es)	2012-06-21	2018-04-18	Miragen Therapeutics Inc	Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
JP6292631B2 (ja) *	2013-02-18	2018-03-14	塩野義製薬株式会社	含窒素複素環構造を有するヌクレオシド及びヌクレオチド
HK1213018A1 (zh)	2013-03-15	2016-06-24	MiRagen Therapeutics, Inc.	橋接雙環核苷
WO2014151835A1 (en)	2013-03-15	2014-09-25	Miragen Therapeutics, Inc	Locked nucleic acid inhibitor of mir-145 and uses thereof
CA2937548C (en)	2014-02-13	2022-10-25	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN106459135A (zh) *	2014-03-16	2017-02-22	米拉根医疗股份有限公司	双环核苷的合成
WO2016003812A1 (en)	2014-07-02	2016-01-07	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
JP6637961B2 (ja)	2014-08-04	2020-01-29	ミラゲンセラピューティクス，インコーポレイテッド	Ｍｙｈ７ｂの阻害剤およびその使用
HK1247617A1 (zh)	2015-01-20	2018-09-28	MiRagen Therapeutics, Inc.	Mir-92抑制剂及其使用
WO2016130943A1 (en)	2015-02-13	2016-08-18	Rana Therapeutics, Inc.	Hybrid oligonucleotides and uses thereof
AU2016270434B2 (en)	2015-06-05	2019-07-11	MiRagen Therapeutics, Inc.	miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
JP6569920B2 (ja) *	2016-01-07	2019-09-04	国立大学法人大阪大学	α−シヌクレイン発現抑制剤
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2019009298A1 (ja) *	2017-07-05	2019-01-10	国立大学法人大阪大学	α－シヌクレイン発現抑制剤
AU2019207625A1 (en)	2018-01-09	2020-07-30	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof
KR102839166B1 (ko)	2018-01-12	2025-07-28	브리스톨-마이어스 스큅 컴퍼니	알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
BR112020013994A2 (pt)	2018-01-12	2020-12-08	Bristol-Myers Squibb Company	Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
BR112020018752A2 (pt)	2018-03-14	2021-01-05	Beth Israel Deaconess Medical Center	Micro-rna e obesidade
US20210317461A1 (en)	2018-08-09	2021-10-14	Verseau Therapeutics, Inc.	Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
EP4269586A1 (en)	2022-04-29	2023-11-01	Johann-Wolfgang-Goethe-Universität Frankfurt am Main	Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)
WO2024010841A2 (en)	2022-07-06	2024-01-11	Molecular Axiom, Llc	Compositions and methods for treating pancreatic cancer
EP4353823A1 (en)	2022-10-12	2024-04-17	Resalis Therapeutics S.r.l.	Inhibitors of micro-rna 22
KR20260007576A (ko)	2023-04-28	2026-01-14	빔 테라퓨틱스, 인크.	변형된 가이드 rna

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59208572D1 (de) *	1991-10-17	1997-07-10	Ciba Geigy Ag	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
JP3756313B2 (ja) *	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2341058A3 (en)	1997-09-12	2011-11-23	Exiqon A/S	Oligonucleotide Analogues

1999
- 1999-05-24 MX MXPA00011473A patent/MXPA00011473A/es unknown
- 1999-05-24 HR HR20000751A patent/HRP20000751A2/hr not_active Application Discontinuation
- 1999-05-24 SK SK1743-2000A patent/SK17432000A3/sk unknown
- 1999-05-24 NZ NZ507913A patent/NZ507913A/xx unknown
- 1999-05-24 SI SI9920038A patent/SI20474A/sl not_active IP Right Cessation
- 1999-05-24 BR BR9911596-4A patent/BR9911596A/pt not_active IP Right Cessation
- 1999-05-24 CA CA002333380A patent/CA2333380A1/en not_active Abandoned
- 1999-05-24 RU RU2000129663/04A patent/RU2211223C2/ru not_active IP Right Cessation
- 1999-05-24 AU AU40100/99A patent/AU757724B2/en not_active Ceased
- 1999-05-24 PL PL99344303A patent/PL344303A1/xx not_active Application Discontinuation
- 1999-05-24 CN CN99809057A patent/CN1311630A/zh active Pending
- 1999-05-24 YU YU73600A patent/YU73600A/sh unknown
- 1999-05-24 WO PCT/US1999/011442 patent/WO1999060855A1/en not_active Ceased
- 1999-05-24 JP JP2000550331A patent/JP2002516256A/ja not_active Withdrawn
- 1999-05-24 HU HU0102152A patent/HUP0102152A3/hu unknown
- 1999-05-24 EP EP99923288A patent/EP1082012A4/en not_active Withdrawn
- 1999-05-24 UA UA2000116545A patent/UA61997C2/uk unknown
- 1999-05-24 IL IL13942099A patent/IL139420A0/xx unknown
- 1999-12-01 US US09/451,708 patent/US6403566B1/en not_active Expired - Lifetime
2000
- 2000-11-03 ZA ZA200006315A patent/ZA200006315B/en unknown
- 2000-11-24 NO NO20005938A patent/NO20005938L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1311630A (zh)	2001-09-05
AU4010099A (en)	1999-12-13
YU73600A (sh)	2003-08-29
HUP0102152A2 (hu)	2001-12-28
EP1082012A4 (en)	2002-01-16
HUP0102152A3 (en)	2002-04-29
MXPA00011473A (es)	2002-04-24
ZA200006315B (en)	2002-02-04
RU2211223C2 (ru)	2003-08-27
US6403566B1 (en)	2002-06-11
CA2333380A1 (en)	1999-12-02
NO20005938L (no)	2001-01-16
BR9911596A (pt)	2001-10-02
JP2002516256A (ja)	2002-06-04
HRP20000751A2 (en)	2001-12-31
NZ507913A (en)	2003-02-28
WO1999060855A1 (en)	1999-12-02
PL344303A1 (en)	2001-10-22
EP1082012A1 (en)	2001-03-14
AU757724B2 (en)	2003-03-06
SI20474A (sl)	2001-08-31
IL139420A0 (en)	2001-11-25
UA61997C2 (en)	2003-12-15
NO20005938D0 (no)	2000-11-24

Publication	Publication Date	Title
RU2211223C2 (ru)	2003-08-27	Новые нуклеозиды, имеющие бициклическую сахарную группировку, и содержащие их олигонуклеотиды
US6833361B2 (en)	2004-12-21	Nucleosides having bicyclic sugar moiety
AU784374C (en)	2007-06-28	Synthesis of 2'-deoxy-L-nucleosides
US6090932A (en)	2000-07-18	Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
CA2502109C (en)	2010-02-23	4'-c-substituted-2-haloadenosine derivative
US6525191B1 (en)	2003-02-25	Conformationally constrained L-nucleosides
CA2421040C (en)	2010-01-12	Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
JP2621123B2 (ja)	1997-06-18	２’‐ジデオキシ‐イソグアノシン類，イソステリック類似体およびイソグアノシン誘導体並びにそれらの使用
EP1964569A2 (en)	2008-09-03	3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
HU199154B (en)	1990-01-29	Process for producing xylophenanosylthymine derivatives
Seela et al.	2008	6-Azauracil or 8-aza-7-deazaadenine nucleosides and oligonucleotides: the effect of 2′-fluoro substituents and nucleobase nitrogens on conformation and base pairing
Carnero et al.	2020	Novel 1′-homo-N-2′-deoxy-α-nucleosides: synthesis, characterization and biological activity
CZ20004181A3 (cs)	2001-05-16	Sloučenina zahrnující nukleosid s 2',4'-můstkem a oligonukleotid od ní odvozený
Hari et al.	2011	2′-O, 4′-C-Methyleneoxymethylene Bridged Nucleic Acids (2′, 4′-BNACOC)
Okello et al.	2013	Methodologies for the Synthesis of Isomeric Nucleosides and Nucleotides of Antiviral Significance
WO1994001445A1 (en)	1994-01-20	Base-protected nucleotide analogs with protected thiol groups
HK1086275A (zh)	2006-09-15	2'-脫氧-l-核苷的合成
HK1086274A (zh)	2006-09-15	2'-脫氧-l-核苷的合成
HK1086577A (zh)	2006-09-22	2'-脫氧-l-核苷的合成
EP1634888A2 (en)	2006-03-15	Synthesis of 2'-deoxy-L-nucleosides